The PACIFIC trial in NSCLC demonstrated that PFS and OS were significantly longer with durvalumab than with placebo, especially in patients with PD-L1 TC ≥ 1%, while safety was similar between the groups [67]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.